Tellgen Corp. Class A

Tellgen Corp. Class A

SSZSE:300642
14.23
CNY
-0.59
(-3.98%)
0.10EPS
178.58P/E
3.38BMarket Cap
Apr 19Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.63
0.97
1.39
1.9
2.04
2.25
2.72
3.01
4.01
4.4
3.33
2.69
2.23
2.44
Basic EPS, GAAP
0.19
0.3
0.54
0.8
0.85
0.87
0.97
0.74
0.99
0.77
0.55
0.21
0.02
0.12
Free Cash Flow per Basic Share
-0.15
0.15
0.22
0.28
0.21
0.1
0.46
0.11
-0.19
0.6
0.15
0.48
0.47
- -
Dividend per Share
- -
0.01
0.04
0.04
0.12
0.15
0.17
0.22
0.22
0.25
0.2
0.16
0.18
0.22
Book Value per Share
0.78
1.08
1.58
2.38
5.53
6.28
7.15
7.74
8.5
8.99
9.31
9.25
8.78
8.87
Tangible Book Value per Share
0.78
1.08
1.49
2.28
5.47
6.21
7.09
7.65
8.42
8.92
9.25
8.94
7.1
7.23
Basic Weighted Avg Shares
122
122
122
122
149
162
162
163
163
163
163
162
163
161
Sales/Revenue/Turnover
77
118
169
231
303
365
441
490
655
716
543
437
364
394
Operating Margin (%)
31.27
35.39
42.85
45.81
46.43
41.73
38.19
26.23
22.24
13.61
13.88
14.66
10.58
10.52
Depreciation Expense
6
9
12
18
24
32
43
55
72
81
78
67
60
- -
Net Income, GAAP
23
36
66
98
127
142
157
121
161
125
89
35
4
19
Effective Tax Rate (%)
13.08
14.89
14.56
13.49
13.84
14.31
13.32
7.54
9.61
5.29
3.19
20.66
- -
23.01
Profit Margin (%)
29.39
30.46
38.83
42.28
41.87
38.84
35.57
24.62
24.61
17.42
16.47
7.91
0.99
4.78
Working Capital
52
75
112
181
729
759
832
834
816
883
798
788
765
816
LT Debt
13
11
10
14
- -
- -
- -
16
12
8
6
91
368
404
Total Equity
95
131
192
289
896
1,026
1,169
1,264
1,396
1,481
1,536
1,518
1,480
1,476
Return on Invested Capital (%)
22.21
26.63
34.69
35.02
20.79
14.6
14.17
9.83
12.07
8.61
5.69
1.98
- -
1.04
Return on Capital (%)
24.96
29.11
38.3
38.73
21.19
14.74
14.31
9.84
12.01
8.68
6.22
2.6
- -
1.4
Return on Common Equity (%)
26.96
31.85
40.68
40.65
21.41
14.74
14.31
9.91
12.12
8.71
5.96
2.28
0.24
1.29

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
19
37
39
LT Borrowings
355
376
397
LT Finance Leases
8
8
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
163
162
162
Market Capitalization
2,688
1,915
3,382

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
882
933
937
Cash, Cash Equivalents & STI
545
612
603
Accounts Receivable, Net
189
134
145
Inventories
101
87
86
Total Current Liabilities
164
140
121
Payables & Accruals
- -
- -
- -
ST Debt
19
37
39
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
31.36%
3.33%
-2.48%
Free Cash Flow
-31.93%
-111.98%
-2.86%
Net Income, GAAP
-9.06%
-33.65%
-89.61%
Sales/Revenue/Turnover
10.25%
-3.47%
-16.7%
Total Cash Common Dividend
31.71%
-3.33%
12.56%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
93
123
105
116
437
2025
75
84
- -
106
364
2026
83
105
100
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.03
0.07
0.11
0.06
0.21
2025
- -
0.01
- -
-0.01
0.02
2026
-0.03
0.11
0.06
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.15
- -
- -
0.16
2025
- -
0.15
- -
0.02
0.18
2026
0.01
0.12
0.07
- -
- -

Company Description

CEO
Jian Er Yao
Full Time Employees
683
Sector
Health services
Industry
Medical/Nursing services
Address
No. 412 Huiqing Road Shanghai SH China 201201
IPO Date
Apr 21, 2017
Business
Tellgen Corporation (300642.SZ) researches, develops, manufactures and distributes in vitro diagnostic (IVD) products with a focus on tumor markers, molecular diagnostics and related testing solutions in China and internationally; headquartered in Shanghai, China, the company was founded in 2003 and listed on the Shenzhen Stock Exchange in 2017. Core offerings encompass tumor marker detection reagents including AFP, CEA, CA125, CA242, SCCA and multi-panel combinations such as the 12-item tumor marker panel, male nine/female eight tumor marker panels, lung cancer three- and five-item panels; HPV nucleic acid detection kits covering HPV27, HPV5+9 (targeting Chinese epidemiology with 16/18/58/52/33 subtypes), HPV2+12; reproductive health products like Y chromosome microdeletion (Y6) test kits compliant with EAA/EMQN guidelines; autoimmune, cardiovascular and inflammation markers; biochemistry kits; DNA methylation tests such as SHOX2/RASSF1A for lung cancer and Septin9 for colorectal cancer; infectious disease detection including COVID-19 molecular tests, Zika/Dengue/Chikungunya (approved in Thailand); PGI/PGII and G17 gastric cancer screening kits; diagnostic instruments and assembly lines like TESMI i100/i200 chemiluminescence immunoassay analyzers, TESMI F4000, NuaBox multiplex PCR systems, ImmunDuo modular automation, Hitachi-compatible流水线, rapid PCR cyclers; and quality control products like multi-tumor marker controls. Platforms include immunofluorescence, chemiluminescence immunoassay, multiplex fluorescent PCR, mass spectrometry and xMAP-based Tellgenplex technology, serving clinical diagnostics, physical exams and precision oncology from screening to prognosis. Recent developments feature the completed acquisition of a 72.9% stake in Wuhan HealthCare Biotechnology Co., Ltd. (HealthCare BIO) for RMB 291 million in August 2025, integrating its FastProbe rapid FISH probes for hematologic malignancies, solid tumors and companion diagnostics to form a full-chain Flow Fluorescence + PCR + FISH oncology strategy with international sales in over 40 countries; a strategic investment in CytoCares (Shanghai) Inc. in October 2025 to build a diagnosis-plus-therapy ecosystem for autoimmune diseases; a RMB 68 million investment in Huihe Bio for its CC312 dry eye pipeline; share repurchases totaling 0.45% of shares from August to September 2025; and subsidiary Wuhan Kanglu Biotechnology's medical device registration acceptance by the National Medical Products Administration in November 2025.